New Biomarkers Predict CAR-T Therapy Outcomes in Multiple Myeloma Treatment

CAR-T cell therapy has emerged as a groundbreaking treatment for relapsed and refractory Multiple Myeloma (RRMM), offering hope to patients with limited treatment options. However, optimizing treatment strategies remains a challenge as newer therapies, such as bispecific antibodies, continue to emerge. Identifying biomarkers that can predict the efficacy of CAR-T therapy is crucial for tailoring treatments and improving patient outcomes.

A recent study conducted by researchers from the Moffitt Cancer Center and published in Blood explored the prognostic value of baseline soluble B-cell maturation antigen (sBCMA) levels and metabolic tumor volume (MTV) in RRMM patients undergoing CAR-T therapy. The retrospective study included 183 patients who had received at least four prior lines of treatment and had data on pre-treatment sBCMA levels (before lymphodepletion chemotherapy) and/or MTV (via PET-CT). The study found that the one-year overall survival rate for these patients was 78%.

The study revealed that high pre-treatment levels of sBCMA were associated with other tumor burden markers (such as bone marrow plasma cells, β2-microglobulin) and inflammation (such as ferritin). Notably, sBCMA levels varied between responders and non-responders, with higher levels observed in primary refractory patients. A sBCMA cutoff of 97.1 ng/mL was found to predict increased CAR-T therapy-related toxicity and a worse progression-free survival (PFS).

Furthermore, high MTV, with a cutoff of 6.3 mL, was associated with shorter PFS and poorer overall survival (OS). However, the correlation between sBCMA and MTV was poor, suggesting that a combined analysis of both biomarkers may help evaluate patients with inconsistent results. For example, patients with low sBCMA and low MTV showed the best prognosis, while those with low sBCMA and high MTV were at a higher risk of treatment failure due to BCMA-low or BCMA-negative plasma cells.

The study emphasizes the potential of sBCMA and MTV as biomarkers for personalizing CAR-T therapy in RRMM, allowing for better management of patients who are candidates for BCMA-targeted treatments. Notably, the half-life of sBCMA (24-36 hours) is shorter than other tumor burden indicators, such as IgG, IgA, and κ/λ light chains, making it a more rapid and reliable marker for assessing treatment effects and residual tumor burden.

These findings are expected to play a pivotal role in refining CAR-T therapy strategies and improving outcomes for RRMM patients, highlighting the importance of personalized, biomarker-guided treatment approaches.